Cost-effectiveness of Finotonlimab in R/M HNSCC Treatment in China
The SCT-I10A-B301 trial shows finotonlimab combined with chemotherapy for R/M HNSCC has an ICER of $112,384.47/QALY, exceeding China's WTP threshold.
Phase III
Oncology / Head and Neck Cancer
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Pharmaceutical companies may need to consider pricing strategies for finotonlimab to enhance its competitive positioning against chemotherapy in China, impacting market access and reimbursement discussions.
Why it matters
The recent cost-effectiveness analysis of finotonlimab in combination with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) reveals that its incremental cost-effectiveness ratio (ICER) significantly exceeds China's willingness to pay (WTP) threshold.
Recommended action
Humanexa recommends Monitor: Humanexa recommends monitoring developments related to finotonlimab's pricing strategies and any new data from ongoing trials. This approach is warranted given the current cost-effectiveness challenges and the potential for significant changes that could affect market access and reimbursement decisions in the near future.
Analysis
Monitor any announcements regarding price adjustments for finotonlimab and further data from ongoing trials that may influence its cost-effectiveness.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.